Abstracts tagged "quality of life"

Abstract Number: 0260 • ACR Convergence 2020
Does Higher Quality of Care in SLE Improve Quality of Life?
Shilpa Arora¹, Patricia Katz², Jinoos Yazdany³, Joel Block¹, Edward Yelin⁴ and Meenakshi Jolly⁵, ¹Rush University Medical Center, Chicago, IL, ²University of California, San Francisco, Novato, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Rush University, Chicago, IL
Background/Purpose: Disease activity, damage and quality of life (QOL) are core outcomes in Systemic lupus erythematosus (SLE). ER visits and hospital admissions (non-routine health care…
Abstract Number: 1072 • ACR Convergence 2020
Sexual Health Impairment in 62 Female Patients with Idiopathic Inflammatory Myopathies
Barbora Hermankova¹, Maja Spiritovic², Sabina Oreska³, Hana Storkanova⁴, Hana Smucrova⁵, Martin Komarc⁶, Martin Klein⁴, Karel Pavelka⁷, Ladislav Šenolt⁷, Jiří Vencovský⁷, Heřman Mann⁴ and Michal Tomcik⁴, ¹Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Hlavni mesto Praha, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ⁶Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare diseases characterized by chronic muscle inflammation and multiple organ involvement. These serious clinical manifestations…
Abstract Number: 1479 • ACR Convergence 2020
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Jasmin Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Ales Janda⁶, Tilmann Kallinich⁷, Prasad T. Oommen⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Norbert Blank¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Department of Pediatrics, University Hospital Ulm, Germany, Ulm, Germany, ⁷Charite, Berlin, Germany, ⁸Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany
Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…
Abstract Number: 0326 • ACR Convergence 2020
Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
Ana-Maria Orbai¹, William Tillett², Suzann Grieb³, James Piercy⁴, Steven Peterson⁵, Elizabeth Holdsworth⁴, Sophie Meakin⁴, Soumya Chakravarty⁶, Nicola Booth⁴ and Laure Gossec⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³John Hopkins University School of Medicine, Baltimore, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Flares in PsA, presenting as periods of acute disease activity, are thought to negatively impact patients’ lives. This has not been extensively studied in…
Abstract Number: 1081 • ACR Convergence 2020
Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies
Valérie Leclair¹, Brett Thombs², Mianbo Wang³, Evelyne Vinet⁴, Alexandra Albert⁵ and Marie Hudson⁶, ¹Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ²Department of Psychology, McGill University, Montreal, QC, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada; Department of Medicine, Université Laval, Québec, QC, Canada., Neuville, Canada, ⁶Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Patient-reported outcomes (PROs) are increasingly used in rheumatology. Such outcomes are under-reported in autoimmune inflammatory myopathies (AIM) especially in incident cohorts. The objective of…
Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Alessandra Alongi¹, Maria Trachana², Valda Stanevicha³, Laura Marinela Ailioaie⁴, Elena Tsitsami⁵, Angelo Ravelli⁶, Alessandro Consolaro⁶ and Nicolino Ruperto⁷, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²Aristotle University of Thessaloniki, Thessaloníki, Greece, ³Riga Stradins University, Riga, Latvia, ⁴Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ⁵Aghia Sophia Childrens Hospital, Athens, Greece, ⁶Università degli Studi di Genova, Genoa, Italy, ⁷Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…
Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Laure Gossec¹, Jessica Walsh², Kaleb Michaud³, Elizabeth Holdsworth⁴, Steven Peterson⁵, Sophie Meakin⁴, Nicola Booth⁴, Soumya Chakravarty⁶, James Piercy⁴ and Alexis Ogdie⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…
Abstract Number: 1102 • ACR Convergence 2020
Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment
Coen van der Meulen¹, Lotte van de Stadt¹, Féline Kroon², Marion Kortekaas¹, Annelies Boonen³, Stefan Böhringer⁴, Monique Reijnierse², Frits Rosendaal², Naghmeh Riyazi⁵, Mirian Starmans⁶, Franktien Turkstra⁷, Jende Van Zeben⁸, CF Allaart² and Margreet Kloppenburg², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴LUMC, Leiden, ⁵HAGA ziekenhuis, the hague, Netherlands, ⁶Zuyderland MC, Heerlen, Netherlands, ⁷Reade, Amsterdam, Netherlands, ⁸Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
Background/Purpose: To investigate whether neuropathic pain is present in patients with inflammatory hand OA, to investigate characteristics of those patients and the impact of neuropathic…
Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Jeffrey Sarazin¹, Ann Impens², Nada Abdulaziz¹, Stacey Anderson³, Leslie Fecher¹, Christopher Lao¹ and Elena Schiopu¹, ¹Michigan Medicine, Ann Arbor, MI, ²Midwestern University, Ann Arbor, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
Abstract Number: 0353 • ACR Convergence 2020
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Laura Coates¹, Philip Mease², Dafna Gladman³, Sandra Navarra⁴, Weibin Bao⁵ and Corine Gaillez⁶, ¹University of Oxford, Oxford, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Santo Tomas, Manila, Philippines, ⁵Novartis Pharmaceuticals Corporation, East Hannover, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: A treat-to-target approach in psoriatic arthritis (PsA) was recommended by EULAR and GRAPPA to achieve remission (REM) or low disease activity (LDA), by regular…
Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Mithu Maheswaranathan¹, Kevin McKenna², Amy Corneli², David Pisetsky³, Megan Clowse⁴ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…
Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
Abstract Number: 0378 • ACR Convergence 2020
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Joseph Merola¹, Peter Taylor², Andrew Bushmakin³, Joseph Cappelleri³, Pamela Young⁴, Rebecca Germino⁵ and Gil Yosipovitch⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶University of Miami, Miami, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
Abstract Number: 1145 • ACR Convergence 2020
Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study
Shanthini Kasturi¹, Lori Lyn Price¹, David Curtis², William Nowell³, Norma Terrin¹, Jane Salmon⁴, Lisa Mandl⁴ and Timothy McAlindon¹, ¹Tufts Medical Center, Boston, MA, ²Global Healthy Living Foundation, New York City, ³Global Healthy Living Foundation, New York City, NY, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Patient-reported outcome measures (PROMs) are powerful tools which can highlight the patient experience of illness. Although PROMs are standard metrics in SLE clinical research,…
Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].